Preclinical evidence for the antihyperalgesic activity of CDPcholine in oxaliplatin-induced neuropathic pain

Journal of B.U.ON.

Volumn 18, Issue 4, 2013, Pages 1012-1018

  Kanat, O ^a   Bagdas, D ^a   Ozboluk, H Y ^a   Gurun, M S ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

CDP choline; Neuropathy; Oxaliplatin; Pain

Indexed keywords

3 AMINOPROPYL(DIETHOXYMETHYL)PHOSPHINIC ACID; CITICOLINE; HEMICHOLINIUM 3; MECAMYLAMINE; NICOTINIC RECEPTOR; OPIATE RECEPTOR; OXALIPLATIN;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; MALE; NEUROPATHIC PAIN; NONHUMAN; PAIN THRESHOLD; RAT;

ANALGESICS; ANIMALS; CYTIDINE DIPHOSPHATE CHOLINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GABA-B RECEPTOR ANTAGONISTS; HYPERALGESIA; INJECTIONS, INTRAVENTRICULAR; MALE; NEURALGIA; NEUROTRANSMITTER UPTAKE INHIBITORS; NICOTINIC ANTAGONISTS; ORGANOPLATINUM COMPOUNDS; PAIN THRESHOLD; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 84893062912     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Grothey A, Goldberg RM. A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin Pharmacother. 2004;5:2159-2170. (Pubitemid 39406117)
2. Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer. 2005;5 (Suppl 1):S38-46.
3. Jaggi AS, Singh N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology 2012;291:1-9.
4. Pasetto LM, D'Andrea MR, Rossi E, Monfardini S. Oxaliplatin-related neurotoxicity:how and why? Crit Rev Oncol Hematol 2006;59:159-108.
5. Sakurai M, Egashira N, Kawashiri T, Yano T, Ikesue H Oishi R. Oxaliplatin-induced neuropathy in the rat:involvement of oxalate in cold hyperalgesia but not mechanical allodynia. Pain 2009;147:165-174.
6. Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A Eckel F, Lersch C. The chemotherapeutic oxaliplatir alters voltage-gated Na(+) channel kinetics on rat sen spry neurons. Eur J Pharmacol 2000;406:25-32.
7. Benoit E, Brienza S, Dubois JM. Oxaliplatin, an anti cancer agent that affects both Na+ and K+ channels ir frog peripheral myelinated axons. Gen Physiol Bio phys 2006;25:263-276. (Pubitemid 44857440)
8. Kagiava A, Tsingotjidou A, Emmanouilides C, Theophilidis G. The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat. Neurotoxicology 2008;29:1100-1106.
9. Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001;85:2293-2297. (Pubitemid 32440704)
10. Secades JJ, Lorenzo JL. Citicolinepharmacological and clinical review, 2006 update. Methods Find Exp Clin Pharmacol 2006;28 (Suppl B):l-56.
11. Arenth PM, Russell KC, Ricker JH, Zafonte RD. CDP-choline as a biological supplement during neurorecoverya focused review. PM R 2011;3(6 Suppl 1):S123-131.
12. Bagdas D, Sonat FA, Hamurtekin E, Sonal S, Gurun MS. The antihyperalgesic effect of cytidine-5'-diphosphate-choline in neuropathic and inflammatory pain models. Behav Pharmacol 2011;22:589-598.
13. Hamurtekin E, Gurun MS. The antinociceptive effects of centrally administered CDP-choline on acute pain models in rats.-the involvement of cholinergic system. Brain Res 2006;1117:92-100. (Pubitemid 44573100)
14. Hamurtekin E, Bagdas D, Gurun MS. Possible in volvement of supraspinal opioid and GABA receptor: in CDP-choline-induced antinociception in acute pair models in rats Neurosci Lett 2007;420:116-121.
15. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pair 1983;16:109-110. (Pubitemid 13058546)
16. Randall LO, Selitto JJ. A method for measurement ol analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther 1957;111:409-419.
17. Ling B, Coudoré-Civiale MA, Balayssac D, Eschaliei A, Coudoré F, Authier N. Behavioral and immunohistological assessment of painful neuropathy inducec by a single oxaliplatin injection in the rat Toxicology 2007;234:176-184. (Pubitemid 46635955)
18. Ling B, Coudoré F, Decalonne L, Eschalier A, Authiei N. Comparative antiallodynic activity of morphine pregabalin and lidocaine in a rat model of neuropathic pain produced by one oxaliplatin injection. Neuropharmacology 2008;55:724-728.
19. Authier N, Balayssac D, Marchand F et al. Animal models of chemotherapy-evoked painful peripheral neuropathies. Neurotherapeutics 2009;6:620-629.
20. Argyriou AA, Polychronopoulos P, Iconomou G Chroni E, Kalofonos HP. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 2008;34:368-377.
21. Bennett BK, Park SB, Lin CS, Friedlander ML, Kieman MC, Goldstein D. Impact of oxaliplatin-induced neuropathy:a patient perspective. Support Care Cancer 2012;20:2959-2967.
22. 2+ channel blockers prevent oxaliplatin-induced cold hyperalgesia and TRPM8 overexpression in rats Mol Pain 2012;8:7.
23. Wang Y, Su DM, Wang RH, Liu Y, Wang H. Antinociceptive effects of choline against acute and inflammatory pain. Neuroscience 2005;132:49-56. (Pubitemid 40380713)
24. Gurun MS, Parker R, Eisenach JC, Vinder M. The effect of peripherally administered CDP-choline in an acute inflammatory pain modekthe role of alpha7 nicotinic acetylcholine receptor. Anesth Analg 2009; 108:16801687.
25. Rowley TJ, McKinstry A, Greenidge E, Smith W, Flood P. Antinociceptive and anti-inflammatory effects of choline in a mouse model of postoperative pain. Br J Anaesth 2010;105:201-207.
26. Damaj MI, Meyer EM, Martin BR. The antinociceptive effects of alpha7 nicotinic agonists in an acute pain model. Neuropharmacology 2000;39:2785-2791.
27. Wurtman RJ, Regan M, Ulus I, Yu L. Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochem Pharmacol 2000;60:989-992.
28. Cavun S, Savci V, Ulus IH. Centrally injected CDP-choline increases plasma vasopressin levels by central cholinergic activation. Fundam Clin Pharmacol 2004:18:71-77. (Pubitemid 38200921)